<DOC>
	<DOCNO>NCT01113710</DOCNO>
	<brief_summary>This non-interventional observational study design gain data Neupro® restless legs syndrome ( RLS ) real life condition line summary product characteristic ( SmPC ) relate effectiveness , tolerability switch practice dopaminergic drug well titration scheme .</brief_summary>
	<brief_title>Non-interventional Study ( NIS ) Patients With Restless Legs Syndrome Daily Practise</brief_title>
	<detailed_description>There total 64 subject record discontinue due Adverse Events . Documentation Visit 2 Visit 3 , reason discontinuation document , available subject . From documentation Adverse Events page Case Report Form , know 100 subject discontinue due Adverse Events . The Last Observation Carried Forward ( LOCF ) method utilized outcome .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>It recommend patient 's treatment accordance local marketing authorization ( MA ) Neupro® The patient must diagnosis moderate severe idiopathic RLS The patient consider reliable capable adhere visit schedule medication administration accord judgment investigator The decision prescribe drug make physician independently his/her decision include patient study Subject inform give ample time opportunity think his/her participation study give write inform data consent Hypersensitivity active substance excipients Magnetic resonance image cardioversion ( see SmPC )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Rotigotine</keyword>
	<keyword>Neupro®</keyword>
	<keyword>Restless Legs Syndrome</keyword>
</DOC>